Evidence map›Paper›PMID 37322040›Full record

ArticleScientific reports2023

Optimized testing strategy for the diagnosis of GAA-FGF14 ataxia/spinocerebellar ataxia 27B.

Céline Bonnet, David Pellerin, Virginie Roth, Guillemette Clément, Marion Wandzel, Laëtitia Lambert, Solène Frismand, Marian Douarinou, Anais Grosset, Ines Bekkour and 20 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Practice Recommendations for Genetic Testing of Ataxias.Annals of clinical and translational neurology · 2025
    Review
  13. Article
  14. Article
  15. GAA-FGF14 Expansions and CACNA1A Variants: Phenotypic Overlap and Diagnostic Implications.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 8 institutions in 6 countries.

Céline Bonnet *Laboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France. ce.bonnet@chru-nancy.fr.
David Pellerin *Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, UK.
Virginie RothLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Guillemette ClémentINSERM-U1256 NGERE, Université de Lorraine, Nancy, France.
Marion WandzelLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Laëtitia LambertINSERM-U1256 NGERE, Université de Lorraine, Nancy, France.
Solène FrismandService de Neurologie, CHRU de Nancy, Nancy, France.
Marian DouarinouService de Neurologie, CHRU de Nancy, Nancy, France.
Anais GrossetService de Neurologie, CHRU de Nancy, Nancy, France.
Ines BekkourService de Neurologie, CHRU de Nancy, Nancy, France.
Frédéric WeberLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Florent GirardierLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Clément RobinLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Stéphanie CacciatoreLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Myriam BronnerLaboratoire de Génétique Médicale, Hôpitaux de Brabois - CHRU de Nancy, Nancy, France.
Carine PouriéINSERM-U1256 NGERE, Université de Lorraine, Nancy, France.
Natacha DreumontINSERM-U1256 NGERE, Université de Lorraine, Nancy, France.
Salomé PuisieuxService de Neurologie, CHRU de Nancy, Nancy, France.
Pablo IruzubietaDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, UK.
Marie-Josée DicaireDepartment of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada.
François EvoyFaculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
Marie-France RiouxFaculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
Armand HocquelService de Neurologie, CHRU de Nancy, Nancy, France.
Roberta La PianaDepartment of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Henry HouldenDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London, London, UK.
Matt C DanziDr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Stephan ZuchnerDr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA.
Bernard BraisDepartment of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada.
Mathilde RenaudINSERM-U1256 NGERE, Université de Lorraine, Nancy, France. m.renaud2@chru-nancy.fr.
Centre Hospitalier Régional et Universitaire de Nancy · FRInserm · FRMontreal Neurological Institute and Hospital · CAUniversité de Sherbrooke · CAUniversity of Miami · USBiomedical Research Networking Center on Neurodegenerative Diseases · ESGerman Center for Neurodegenerative Diseases · DENational Hospital for Neurology and Neurosurgery · GB

Funding

Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

Dominantly inherited GAA repeat expansions in FGF14 are a common cause of spinocerebellar ataxia (GAA-FGF14 ataxia; spinocerebellar ataxia 27B). Molecular confirmation of FGF14 GAA repeat expansions has thus far mostly relied on long-read sequencing, a technology that is not yet widely available in clinical laboratories. We developed and validated a strategy to detect FGF14 GAA repeat expansions using long-range PCR, bidirectional repeat-primed PCRs, and Sanger sequencing. We compared this strategy to targeted nanopore sequencing in a cohort of 22 French Canadian patients and next validated it in a cohort of 53 French index patients with unsolved ataxia. Method comparison showed that capillary electrophoresis of long-range PCR amplification products significantly underestimated expansion sizes compared to nanopore sequencing (slope, 0.87 [95% CI, 0.81 to 0.93]; intercept, 14.58 [95% CI, - 2.48 to 31.12]) and gel electrophoresis (slope, 0.84 [95% CI, 0.78 to 0.97]; intercept, 21.34 [95% CI, - 27.66 to 40.22]). The latter techniques yielded similar size estimates. Following calibration with internal controls, expansion size estimates were similar between capillary electrophoresis and nanopore sequencing (slope: 0.98 [95% CI, 0.92 to 1.04]; intercept: 10.62 [95% CI, - 7.49 to 27.71]), and gel electrophoresis (slope: 0.94 [95% CI, 0.88 to 1.09]; intercept: 18.81 [95% CI, - 41.93 to 39.15]). Diagnosis was accurately confirmed for all 22 French Canadian patients using this strategy. We also identified 9 French patients (9/53; 17%) and 2 of their relatives who carried an FGF14 (GAA)

Indexed as

Friedreich AtaxiaSpinocerebellar AtaxiasCanadaFibroblast Growth FactorsHumansTrinucleotide Repeat Expansionfibroblast growth factor 14Fibroblast Growth Factors

Identifiers

PMID37322040
PMCPMC10272173
OpenAlexW4380853691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.